ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
Wiestner, Adrian U.; Skarzynski, Martin W.; Lindorfer, Margaret A.; Taylor, Ronald P.; Rader, Christoph; Vire, Berengere
Feb 2019
Abstract
An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.
Methods of Selecting Binding Reagents
Mallick, Parag; Egertson, Jarrett
Feb 2019
Abstract
Methods and systems are provided herein for selecting an affinity reagent which binds a desired peptide epitope in a plurality of sequence contexts. The method relies on obtaining a peptide library, each peptide having the sequence αΧβ, wherein X is the desired peptide epitope, wherein each of a and β comprise an amino acid, using the peptide library to select an affinity reagent.
Novel targets of acinetobacter baumannii
Urwyler, Simon; Haake, Markus; Rudolf, Michael
Jan 2019
Abstract
The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.
Marker Sequences for Diagnosing and Stratifying Systemic Sclerosis Patients
The invention relates to a method for identifying markers for systemic sclerosis (scleroderma, SSc) and to the markers identified by means of said method, which can differentiate between SSc and other autoimmune diseases and between different SSc sub-groups. The invention also relates to panels, diagnostic means, and test kits which comprise said markers and to the use and application thereof, for example for the diagnosis, prognosis, and therapy control for SSc. The invention further relates to methods for screening and validating active ingredients for use in SSc sub-groups.
Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine antibodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.
